RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
“We are short $CODX due to its CFO’s checkered history,” the research shop wrote in a tweet, coming after Co-Diagnostics (NASDAQ:CODX) shares have rallied hard recently on the back of testing data.
Shares fell 18% in Thursday’s trading after being up 63%, 136% and ~2,600% over the past week, month and 6 month period, respectively.
Hindenburg writes that the test quality has been “rated one of the worst” despite the co.’s claims of 100% sensitivity and specificity. It is a “third-tier” option among competitors, the note continues.
With regards to the CFO allegations, Hindenburg writes that the CFO has a history of ties to a firm accused of stock promotion.
COVID-19 test developer Co-Diagnostics shares surged 30% on Wednesday following a disappointing Abbott release.
Aurora Cannabis (NYSE:ACB) fiscal Q3 results:
Cash in the bank at quarter’s end of $230.2M, with $154.6M cash use in FQ3 down 43% from previous quarter.
Company remains on track to have positive adjusted EBITDA in FQ2021.
The conference call is set for 5 ET.
Net revenue: $75.5M (+34.8%); Canadian medical cannabis net revenue: $27.0M (+5.5%); consumer cannabis net revenue: $41.5M (+23.9%); cannabis net revenue: $69.6M (+32.1%).
Non-GAAP EBITDA: ($50.9M) (+36.5%). Aims to achieve positive EBITDA by FQ1 2021.
Cannabis inventory and biological assets: $244.5M (+12.8%).
Product cost/gram: $0.85 (-3.4%).
Kilograms produced: 36,207 (+17.8%).
Kilograms sold: 12,729 (+34.0%).
Shares up 13% after hours.
Nano cap Akers Biosciences (AKER +31.2%) bucks the broad market selloff on more than triple normal volume on its announcement that development partner Premas Biotech has completed a prototype of a COVID-19 vaccine.
Under the terms of their collaboration, Premas is responsible for development through proof-of-concept.
The companies are moving forward with talks with regulators in India while continuing to develop their regulatory strategy in the U.S. They have also established a manufacturing protocol and have initiated large-scale production studies.
The company tomorrow will open more than 50 drive-thru COVID-19 test sites in five states – Arizona, Connecticut, Florida, Massachusetts, and Pennsylvania – and expects to have up to 1K locations across the country by the end of the month. The goal is to be able to do up to 1.5M tests per month.
Self-swabs will be performed at the sites. Testing is to be done at a third-party lab, with results in about three days.
CVS -1.1% today.
Aytu BioScience (NASDAQ:AYTU): Q3 GAAP EPS of -$0.15 misses by $0.10.
Revenue of $8.2M (+244.5% Y/Y) beats by $2.39M.
Cash and equivalents of $62.5M.
Shares +8.4%.
